The Challenge of Dysglycemia and Coronary Heart Disease
DOI:
https://doi.org/10.17140/HROJ-4-e008Abstract
The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally, and although
there is a small increase in the incidence of type 1 diabetes mellitus, T2DM accounts
for 95% of all individuals with diabetes.1 A high prevalence of undiagnosed glucose abnormalities
has been demonstrated in patients with acute coronary syndrome (ACS) including acute
myocardial infarction (AMI),2 and several studies have shown that newly detected glucose
metabolism abnormalities in the form of impaired glucose tolerance and diabetes represent an
independent risk for cardiovascular mortality and morbidity.3,4 There seems to be a curvilinear
relation between post-oral glucose tolerance test, glucose levels and the risk for cardiovascular
disease, and the risk increases already in the non-diabetic range of glucose levels.
References
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87: 4-14. doi: 10.1016/j.diabres.2009.10.007
Bartnik M, Rydén L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004; 25: 1880-1890. doi: 10.1016/j.ehj.2004.07.027
Lenzen M, Rydén L, Öhrvik J, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influ-ence on 1-year outcome in patients with coronary artery disease: A report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006; 27: 2969-2974. doi: 10.1093/eurheartj/ehl363
Kuhl J, Jörneskog G, Wemminger M, Bengtsson M, Lundman P, Kalani M. Long-term clinical outcome in patient with acute coronary syndrome and dysglycaemia. Cardiovasc Diabetol. 2015; 14: 120. doi: 10.1186/s12933-015-0283-3
Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: Pathophysiology, clinical censequences, and medical therapy: Part I. Eur Heart J. 2013; 34: 2436-2446. doi: 10.1093/eurheartj/eht149
Vazanna N, Ranali P, Cuccurullo C, et al. Diabetes mellitus and thrombosis. Thromb Res. 2012; 129: 371-377. doi: 10.1016/j. thromres.2011.11.052
Deedwania P, Kosiborod M, Barrett E, et al. American Heart Association Diabetes Committee of the Council on Nutrition, Physi-cal Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: A scientific statement from the American Heart As-sociation Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008; 117: 1610-1619. doi: 10.1161/CIRCULATIONAHA.107.188629
Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF. In-hospital peak glycemia and prognosis in STEMI patients without earlier known diabetes. Eur J Cardiovasc Prev Rehabil. 2010; 17(4): 419-423.
Verouden NJW, Haeck JDE, Kuijt WJ, et al. Clinical and angiographic predictors of ST-segment recovery after primary percuta-neous coronary intervention. Am J Cardiol. 2010; 105: 1692-1697. doi: 10.1016/j.amjcard.2010.01.343
Romano M, Buffoli F, Tomasi L, et al. The no-reflow phenomenon in acute myocardial infarction after primary angio-plasty: Incidence, predictive factors, and long-term outcomes. J Cardiovasc Med (Hagerstown). 2008, 9: 59-63. doi: 10.2459/ JCM.0b013e328028fe4e
Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003; 41: 1-7. doi: 10.1016/S0735-1097(02)02626-8
Marso SP, Miller T, Rutherford BD, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol. 2007; 100: 206-210. doi: 10.1016/j.amjcard.2007.02.080
Ishihara M, Kagawa E, Inoue I, et al. Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mor-tality after acute myocardial infarction in the coronary intervention era. Am J Cardiol. 2007; 99: 1674-1679. doi: 10.1016/j.amj-card.2007.01.044
Timmer JR, van der Horst IC, de Luca G, et al. Comparison of myocardial perfusion after successful primary percutaneous coro-nary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol. 2005; 95: 1375-1377. doi: 10.1016/j.amjcard.2005.01.088
De Luca G, Małek LA, Maciejewski P, et al. Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the POLISH STEMI registry. Atherosclerosis. 2010; 210(2): 516-520. doi: 10.1016/j.atherosclerosis.2009.12.012
De Luca G, Gibson CM, Bellandi F, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfu-sion, and higher mortality in patients with ST segment elevation myocardial infarction treated with primary angioplasty and glyco-protein IIb-IIIa inhibitors. Atherosclerosis. 2009; 207(1): 181-185. doi: 10.1016/j.atherosclerosis.2009.03.042
De Luca G, Ernst N, van’t Hof AWJ, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J. 2006; 151: 1256-1259. doi: 10.1016/j.ahj.2005.06.047
Madsen MM, Busk M, Søndergaard HM, et al. Does diabetes mellitus abolish the beneficial effect of primary coronary an-gioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy). Am J Cardiol. 2005; 96: 1469-1475. doi: 10.1016/j.amjcard.2005.07.053
Papadogeorgos NÖ, Jörneskog G, Bengtsson M, Kahan T, Kalani M. Severely impaired microvascular reactivity in diabetic patients with an acute coronary syndrome. Cardiovasc Diabetol. 2016; 15: 66. doi: 10.1186/s12933-016-0385-6
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.